- Home
- KNOP vs IPHA Comparison
KNOP vs IPHA Comparison
Compare KNOP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | IPHA |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United Kingdom | France |
| Employees | N/A | 174 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 119.1M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNOP | IPHA |
|---|---|---|
| Price | $9.15 | $1.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 58.3K | 11.9K |
| Earning Date | 03-16-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.11 | $28.31 |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.45 | $1.31 |
| 52 Week High | $11.15 | $2.63 |
Technical Indicators
Market Signals| Indicator | KNOP | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 25.36 | 21.88 |
| Support Level | $8.84 | N/A |
| Resistance Level | $9.12 | $1.88 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 15.20 | 2.79 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.